Ed Esplin, SVP of Medical Affairs at Biocartis, shared on X:
“Our analyses revealed strong genetic influences on genome stability, oncogenic selection, and multiple instances of epistatic germline, somatic interactions that shaped subsequent cancer evolution.
It raises challenging questions about whether germline genetic background should be considered alongside somatic alterations… in the design and interpretation of translational cancer research.
Further evidence for Universal Germline Genetic Testing in Patients With Solid Tumor Cancer here.”
Title: Genetic background sets the trajectory of experimental cancer evolution
Authors: Sarah J. Aitken, Frances Connor, Christine Feig, Tim F. Rayner, Margus Lukk, Juliet Luft, Stuart Aitken, Claudia Arnedo-Pac, James F. Hayes, Michael D. Nicholson, Ailith Ewing, Vasavi Sundaram, Jan C. Verburg, John Connelly, Craig J. Anderson, Mikaela Behm, Susan Campbell, Maëlle Daunesse, Vera B. Kaiser, Elissavet Kentepozidou, Oriol Pich, Aisling M. Redmond, Javier Santoyo-Lopez, Inés Sentís, Lana Talmane, Liver Cancer Evolution Consortium, Paul Flicek, Núria López-Bigas, Colin A. Semple, Martin S. Taylor, Duncan T. Odom.
You can also read ‘ACGT Investigator Award in Cell & Gene Therapy for Solid Tumor Cancers 2026‘
